The short answer. There isn't much data on Liver Support yet — 12 mentions, 3 with a clear outcome — so treat these numbers as anecdotal. It is well studied — 30 meta-analyses on PubMed.
From 12 mentions in total — the rest didn't say how it went and aren't counted.
Of the people who reported each effect, the share who said it got better.
Systematic reviews and meta-analyses from PubMed, with their published conclusions.
3+ meta-analyses or systematic reviews and 10+ randomized controlled trials in humans. The grade measures how much human research exists — read the conclusions below for what it found.
Conclusion: Because of the limited data, there is a need for more randomized control trials. Evaluating cost and patient preference would aid in differentiating the systems.
PubMed 32918840 ↗Conclusion: ELS systems appear to improve survival in acute liver failure. There is, however, no evidence that they improve survival in acute-on-chronic liver failure.
PubMed 21462172 ↗Conclusion: In this up-to-date meta-analysis, significant 1, 3-month and up to 1-year survival benefit was noted among patients with ACLF treated with PLEX compared to SMT.
PubMed 40265656 ↗Conclusion: ECLS may reduce mortality and improve HE in patients with ALF and ACLF. The effect on other outcomes is uncertain. However, the evidence is limited by risk of bias and imprecision, and larger trials are needed to better determine the effect of ECLS on patient-important outcomes.
PubMed 31588983 ↗As stated by users — not a recommendation. Follow the label or your doctor.
How often each side effect came up across all reports.
First-hand experiences, quoted verbatim. We show one positive and one negative where both exist.
“this is the only thing I've been able to take that stops me from having regular emergency bowel movements”
User data from public discussions; research from PubMed. Information only, not medical advice — talk to a doctor before starting, stopping or combining anything. Data updated October 3, 2026. How we rate